Dergiler / KONURALP TIP DERGİSİ / 2026 / Volume: 18 Issue: 3

The Effect of Serum Vaspin and Adiponectin Levels on Coronary Slow Flow

Gülşah Aktüre(DUZCE UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0002-8389-5174
Osman Kayapinar(DUZCE UNIVERSITY, FACULTY OF MEDICINE)0000-0001-6607-895X
Cem Özde(DUZCE UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0001-8846-9185
Gökhan Coşkun(DUZCE UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0002-3587-9612
Ahmet Egemen Sayın(DUZCE UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0002-4172-561X
Ensar Ekşi(DUZCE UNIVERSITY, SCHOOL OF MEDICINE, MEDICINE PR.)0000-0003-0136-2989
Sayfa
—
Yayın Tarihi
2026-10-27
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Serum vaspin levels were significantly elevated in patients with CSF, suggesting a possible association between increased circulating vaspin concentrations and coronary slow flow.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: Coronary slow flow (CSF) is an angiographic finding characterized by delayed distal vessel opacification in the absence of significant coronary artery disease.
📊
Temel Bulgular & Veri:Materials and Methods: The study included 40 patients with CSF and 38 patients with normal coronary flow who underwent elective coronary angiography.
💡
Sonuç & Katkı:Conclusion: Serum vaspin levels were significantly elevated in patients with CSF, suggesting a possible association between increased circulating vaspin concentrations and coronary slow flow.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Coronary slow flow · vaspin · adiponectin

Abstract

Aim: Coronary slow flow (CSF) is an angiographic finding characterized by delayed distal vessel opacification in the absence of significant coronary artery disease. Although endothelial dysfunction, inflammation, and occult atherosclerosis have been proposed as possible mechanisms, its pathogenesis remains unclear. This study aimed to investigate the association between serum adiponectin and vaspin levels and coronary slow flow. Materials and Methods: The study included 40 patients with CSF and 38 patients with normal coronary flow who underwent elective coronary angiography. Coronary blood flow was assessed using the Thrombolysis in Myocardial Infarction frame count method, and serum adiponectin and vaspin levels were measured in all participants. Results: Adiponectin levels did not differ significantly between the CSF and normal coronary flow groups. Vaspin levels were significantly higher in the CSF group than in the normal coronary flow group (p < 0.001). Conclusion: Serum vaspin levels were significantly elevated in patients with CSF, suggesting a possible association between increased circulating vaspin concentrations and coronary slow flow.

🔖

Bu Makaleye Atıf Yap

Aktüre, G., Kayapinar, O., Özde, C., Coşkun, G., Sayın, A. E., Ekşi, E. (2026). The Effect of Serum Vaspin and Adiponectin Levels on Coronary Slow Flow. KONURALP TIP DERGİSİ, Volume: 18 Issue: 3. https://doi.org/10.18521/ktd.1596120

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (27)

  1. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon- A new coronary microvascular disorder. Cardiology. 2002;97(4):197-202. doi:10.1159/000063121.
  2. Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow: prevalence and clinical correlations. Circ J. 2012;76(4):936-42. doi:10.1253/circj.cj-11-0959.
  3. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, et al. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375-81. doi:10.1002/(SICI)1097-0304(199604)37:4 3.0.CO;2-8.
  4. Wang X, Geng LL, Nie SP. Coronary slow flow phenomenon: a local or systemic disease? Med Hypotheses. 2010;75(3):334-7. doi:10.1016/j.mehy.2010.03.016.
  5. Shah A, Mehta N, Reilly MP. Adipose inflammation, insulin resistance, and cardiovascular disease. JPEN J Parenter Enteral Nutr. 2008;32(6):638-44. doi:10.1177/0148607108325251.
  6. Ohman MK, Wright AP, Wickenheiser KJ, Luo W, Eitzman DT. Visceral adipose tissue and atherosclerosis. Curr Vasc Pharmacol. 2009;7(2):169-79. doi:10.2174/157016109787455680.
  7. Kadoglou NP, Gkontopoulos A, Kapelouzou A, Fotiadis G, Theofilogiannakos EK, Kottas G, et al. Serum levels of vaspin and visfatin in patients with coronary artery disease–Kozani Study. Clin Chim Acta. 2011;412(1-2):48-52. doi:10.1016/j.cca.2010.09.012.
  8. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine. 2012;41(2):176-82. doi:10.1007/s12020-011-9572-0.
  9. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs. 2008;17(3):327-33. doi:10.1517/13543784.17.3.327.
  10. Choi SH, Kwak SH, Lee Y, Moon MK, Lim S, Park YJ, et al. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol (Oxf). 2011;75(5):628-35. doi:10.1111/j.1365-2265.2011.04095.x.
  11. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system. Cardiovasc Res. 2007;74(1):11-8. doi:10.1016/j.cardiores.2006.10.009.
  12. Bełtowski J, Jamroz-Wiśniewska A, Widomska S. Adiponectin and its role in cardiovascular diseases. Cardiovasc Hematol Disord Drug Targets. 2008;8(1):7-46. doi:10.2174/187152908783884920.
  13. Gibson CM, Cannon CP, Daley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879-88. doi:10.1161/01.cir.93.5.879.
  14. Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105(5):546-9. doi:10.1161/hc0502.104540.
  15. Szmitko PE, Wang CH, Weisel RD, Almeida JR, Anderson TJ, Verma S. New markers of inflammation and endothelial cell activation. Circulation. 2003;108:1917-23. doi:10.1161/01.CIR.0000089190.95415.9F.
  16. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003;278(45):45021-6. doi:10.1074/jbc.M307878200.
  17. Hattori Y, Suzuki M, Hattori S. Globular adiponectin upregulates nitric oxide production in vascular endothelial cells. Diabetologia. 2003;46(11):1543-9. doi:10.1007/s00125-003-1224-3.
  18. Spranger J, Mohlig M, Wegewitz U, Ristow M, Pfeiffer AF, Schill T, et al. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome. Clin Endocrinol. (Oxf.) 2004;61(6):738-46. doi:10.1111/j.1365-2265.2004.02159.x.
  19. Wolf AM, Wolf D, Rumpold H, Enrich B, Tilg H. Adiponectin induces the anti-inflammatory cytokines IL-10 and IL-1RA in human leukocytes. Biochem Biophys Res Commun. 2004;323(2):630-5. doi:10.1016/j.bbrc.2004.08.145.
  20. Sezgin AT, Sigirci A, Barutcu I, Topal E, Sezgin N, Ozdemir R, et al. Vascular endothelial function in patients with slow coronary flow. Coron Artery Dis. 2003;14(2):155-61. doi:10.1097/00019501-200304000-00008.
  21. Mosseri M, Yarom R, Gotsman MS, Hasin Y. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986;74(5):964-72. doi:10.1161/01.cir.74.5.964.
  22. Camsarl A, Pekdemir H, Cicek D, Polat G, Akkus MN, Döven O, et al. Endothelin-1 and nitric oxide concentrations and their response to exercise in patients with slow coronary flow. Circ J. 2003;67(12):1022-8. doi:10.1253/circj.67.1022.
  23. Selcuk H, Selcuk MT, Temizhan A, Maden O, Saydam GS, Ulupinar H, et al. Decreased plasma concentrations of adiponectin in patients with slow coronary flow. Heart Vessels. 2009;24(1):1-7. doi:10.1007/s00380-008-1074-5.
  24. Jung CH, Lee WJ, Hwang JY, Seol SM, Kim YM, Lee YL, et al. Vaspin protects endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun. 2011;413(2):264-29. doi:10.1016/j.bbrc.2011.08.083.
  25. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A. 2005;102(30):10610-5. doi:10.1073/pnas.0504703102.
  26. Jung CH, Lee WJ, Hwang JY, Lee MJ, Seol SM, Kim YM, et al. Vaspin increases nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS One. 2012;7(12):e52346. doi:10.1371/journal.pone.0052346.
  27. Kobat MA, Celik A, Balin M, Altas Y, Baydas A, Bulut M, et al. The investigation of serum vaspin level in atherosclerotic coronary artery disease. J Clin Med Res. 2012;4(2):110-3. doi:10.4021/jocmr841w.